This past March, 20 surveys were sent to oncology clients and their caregivers to evaluate the patient experience with the Oncology Nurse Practitioner (ONP). The survey consisted of a brief series of six questions with tick box responses (Yes, No, N/A), and participants had the opportunity to make additional comments. There were a total of 15 responses from patients or their caregivers.
The following six questions were asked:
Did the Nurse Practitioner listen to the problems and symptoms that were bothering you?
Did the Nurse Practitioner clearly explain the purpose and importance of tests, treatments, including any risks? (if any ordered)
Did the Nurse Practitioner clearly explain the purpose and importance of any referrals?
Did you feel satisfied with the outcome after your dealings with the Nurse Practitioner?
Did the Nurse Practitioner give you enough opportunity and time for your questions?
Would you be happy to have the Nurse Practitioner help you with your care again as needed?
Ninety percent of the 15 respondents answered all six questions with YES.
Ten percent of the 15 respondents answered one out of six questions with N/A.
Additional comments from patients and caregivers:
Patients highlighted the availability and support provision as a great attribute of the ONP. Many felt that information delivery and the offer of a “listening ear” relieved emotions and anxiety in relation to their cancer diagnosis and treatment. Patients expressed their gratitude towards the service and placed emphasis on the caring and professional attitude of the ONP.
The purpose of the survey was to investigate whether the ONP was able to provide quality of care, and to demonstrate the level of client satisfaction.
The results indicate that there is high client satisfaction. Very positive outcomes regarding quality of care and information delivery were consistent across all responses. The survey also suggested strong support for the role of the Oncology Nurse Practitioner from the patient's point of view.
Does your cancer center routinely conduct patient satisfaction surveys specifically focused on the care delivered by nurse practitioners?
FDA Approves Onivyde for Advanced Pancreatic Cancer Marijke Vroomen Durning, RN, 10/27/2015 3 On October 22, 2015, the US Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection, Merrimack Pharmaceuticals, Inc.), in combination with fluorouracil ...